Actively Recruiting
Radiotherapy Combined With Endostatin and Capecitabine for NPC
Led by Zhejiang Cancer Hospital · Updated on 2022-08-24
41
Participants Needed
7
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Radiotherapy combined with recombinant human endostatin and capecitabine for patients with nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.
CONDITIONS
Official Title
Radiotherapy Combined With Endostatin and Capecitabine for NPC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed non-keratinizing nasopharyngeal carcinoma confirmed by tissue exam
- Tumor staged as T3-4N1 or N2-3 without distant metastasis
- Karnofsky performance score greater than 70
- Adequate blood counts: leucocytes 800/bcL or more, hemoglobin 90 g/L or more, platelets 100,000/bcL or more
- Normal liver function with ALT and AST less than 1.5 times upper normal limit, ALP less than 2.5 times upper limit, and normal bilirubin
- Adequate kidney function with creatinine clearance 60 ml/min or higher
- Written informed consent given
- Tumor showed stable or progressive disease after neoadjuvant chemotherapy
You will not qualify if you...
- Keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma
- Treatment intended for palliative care
- Previous cancers except treated basal or squamous skin cancers or in situ cervical cancer
- Pregnant or breastfeeding
- Previous radiotherapy except for small skin cancers outside planned treatment area
- Previous chemotherapy or surgery to primary tumor or lymph nodes (except diagnostic biopsy)
- Severe medical conditions such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, or emotional disorders
- Tumor showed complete or partial response after neoadjuvant chemotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
2
the First Hospital of Jiaxing
Jiaxing, Zhejiang, China, 314000
Actively Recruiting
3
Jinhua Central Hospital
Jinhua, Zhejiang, China, 321000
Actively Recruiting
4
The Central Hospital of Lishui City
Lishui, Zhejiang, China, 323000
Actively Recruiting
5
Ningbo First Hospital
Ningbo, Zhejiang, China, 315000
Actively Recruiting
6
Ningbo Medical Center Lihuili Eastern Hospital
Ningbo, Zhejiang, China, 315000
Actively Recruiting
7
People's Hospital of Quzhou
Quzhou, Zhejiang, China, 324000
Actively Recruiting
Research Team
T
Ting Jin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here